🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congrats to our fellow Chadi Hage Chehade for rapid-oral ASCO #ASCO25 (Ab#11014)👉bit.ly/3FnSyfM👉In pts (n~196K) w/ advanced cancers with approved targeted therapies👉Most do not receive NGS testing, & many receive late in the disease course Umang Swami OncoAlert UroToday.com

Fantastic presentation by Renee Maria Saliby discussing our work evaluating MAdCAM-1, a circulating surrogate of gut dysbiosis, as a biomarker in patients with mRCC! #ASCO25 ASCO Toni Choueiri, MD Carolina Alves Costa Silva, MD, PhD OncoAlert

Hard to describe how big of a moment that was! Congrats Dr Renee Maria Saliby for a brilliant ASCO presentation! You make us all proud! And kudos to the whole team behind this work Marc Machaalani Carolina Alves Costa Silva, MD, PhD. It truly takes a village!

#ASCO2025 Powerful letter from ASCO #DailyNews Editor Neeraj Agarwal, MD, FASCO “In the fight against cancer, we are united by purpose.” Thx for all your hard work & dedication to making this the most valuable free resource for oncology professionals 🌏 by bringing key insights from

🏥 Quality cancer care is more than treatment—it's environment, equity, time, and tech. Don't miss the #ASCO25 session on Health Services Research, covering: 🌍 Env. burden & cancer 🏠 Housing & forgone care 💸 Medical debt ⏱️ Time costs 🧬 NGS use 📈 QoL vs OS more!

"Utilization and timing of first tumor next-generation sequencing testing in patients with five most common cancers in the USA." A sizeable # of pts either do not undergo NGS or have their 1st NGS very late in the course of disease (i.e. w/in 3 mo of death). #ASCO25 Chadi Hage Chehade

🌟Great presentation by Chadi Hage Chehade at #ASCO25!! Utilization and timing of NGS in pts w/ 5 most common cancers in the US👉Many pts either don’t receive NGS or have the first NGS very late 👇ASCO OncoAlert Neeraj Agarwal, MD, FASCO Umang Swami Flatiron Health UroToday.com

👉🏻 Our very own Chadi Hage Chehade presenting ASCO a real-world study showing most patients do not undergo NGS testing, and a substantial proportion receive it only near end of life—limiting its clinical utility and impact on treatment decisions. #ASCO25 GU Cancer Research Program @HuntsmanCancer Neeraj Agarwal, MD, FASCO

Nicolas Sayegh, MD Chadi Hage Chehade ASCO GU Cancer Research Program @HuntsmanCancer Umang Swami Georges Gebrael Sumanta K. Pal, MD, FASCO Petros Grivas Zeynep Irem Ozay, MD Benjamin L Maughan Utah IM CMRs Eddy Saad jc UroToday.com Congrats Chadi Hage Chehade for the fantastic oral presentation at the ASCO #ASCO25 Proud of you. GU Cancer Research Program @HuntsmanCancer University of Utah University of Utah Department of Internal Medicine Congrats to Umang Swami Yeonjung Jo

Great poster session this morning with Nicolas Sayegh, MD highlighting work in #prostatecancer TMB & MSI-H w/ real world IO outcomes Foundation Medicine! Truly a star resident UTSW Simmons Cancer Center UTSW Internal Medicine co-mentored by me & Neeraj Agarwal, MD, FASCO. Look out for his fellowship apps this fall! #ASCO25

👉🏻 Superstar Zeynep Irem Ozay, MD presenting ASCO our real-world data showing lutetium has better survival outcomes than cabazitaxel in post-ARPI/docetaxel mCRPC patients. #ASCO25 ASCO #ProstateCancer GU Cancer Research Program @HuntsmanCancer Neeraj Agarwal, MD, FASCO OncoAlert UroToday.com

🌟Great poster presentation by Nicolas Sayegh, MD at #ASCO25! Real-world pts with mCRPC👉TMB-H (without MSI-H) & MSI-H have similar outcomes on ICI Flatiron Health MSI-H detected by ctDNA is a predictive biomarker Neeraj Agarwal, MD, FASCO Ryon Graf, PhD Umang Swami UTSW Simmons Cancer Center OncoAlert UroToday.com

Stellar presentation ASCO #ASCO25 by trailblazer Rana McKay, MD, FASCO on ETCTN trial with radium +|- olaparib in mCRPC #prostatecancer 👉rPFS ⬆️ with the combo w/wo HRRm👇Data continues to reinforce role of PARPi in rationale combinations Toni Choueiri, MD (mentor), UroToday.com OncoAlert

Adjuvant Nivolumab in MIUC – Real-World Data with a Focus on Disparities led by Alex Chehrazi-Raffle, MD A quick tweetorial 🧵 ⁉️ Can real-world outcomes of adjuvant nivolumab match those from clinical trials? And how does it perform in underrepresented groups? ➡️We evaluated 253 patients

Our researchers made a strong showing at #ASCO25 —sharing bold ideas, breakthrough science, and real-world insights to improve cancer care. We’re proud of our team’s dedication to advancing research on a national stage.

Excited to see our work published in Clinical Cancer Research ! Real-world pts w/ mHSPC #prostatecancer w/ HRRalt had worse survival than those w/ non-altered HRR 👉bit.ly/3TsOw9i👇 Grateful for terrific support from team Ryon Graf, PhD Umang Swami Neeraj Agarwal, MD, FASCO UroToday.com OncoAlert

Congrats Chadi Hage Chehade for this impactful study. You are a superstar ⭐️

Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer aacrjournals.org/clincancerres/… Research has shown that around 30% of advanced #ProstateCancer patients have Homologous Recombination / DNA Damage

GU Research Digest for the week of June 14 - 20: a selection of publications about GU cancers in high-impact journals. Search the PMIDs on pubmed.ncbi.nlm.nih.gov to read!

Real-world treatment delays between lutetium-177 and cabazitaxel in advanced #ProstateCancer. Yeonjung Jo & Umang Swami join Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute to discuss research comparing time from medication order to administration of cabazitaxel vs lutetium-177 in #mCRPC